Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status

Affiliations

• ¹ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan. shimomura_0119@yahoo.co.jp.
• ² Center for Community-based Healthcare Research and Education, Shimane University, Shimane, Japan.
• ³ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
• ⁴ Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
• ⁵ Department of hematology, Toranomon Hospital, Tokyo, Japan.
• ⁶ Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
• ⁷ Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
• ⁸ Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
• ⁹ Division of Hematology, Saitama Medical Center Jichi Medical University, Saitama, Japan.
• ¹⁰ Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
• ¹¹ Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
• ¹² Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
• ¹³ Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
• ¹⁴ Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
• ¹⁵ Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
• ¹⁶ Preparation Department, Japanese Red Cross Kinki Block Blood Center, Osaka, Japan.
• ¹⁷ Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
• ¹⁸ Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
• ¹⁹ Nagoya University Graduate School of Medicine, Nagoya, Japan.
• ²⁰ Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan.